Key result
Robotic mitral valve repair for degenerative MR achieves ~94% freedom from reoperation at 36 months.
Why the study?
Outcomes of robotic mitral valve repair for degenerative mitral regurgitation in a European single-centre experience were reported to evaluate feasibility and safety.
Does robotic mitral valve repair provide safe and durable outcomes in patients with degenerative mitral regurgitation?
Cohort (n=134)
No
Does robotic mitral valve repair provide safe and durable outcomes in patients with degenerative mitral regurgitation?
Robotic mitral valve repair for degenerative mitral regurgitation is safe and associated with excellent early and midterm durability.
No hospital mortality supports short-term safety of robotic MV repair; leaves open need for RCTs on durability versus conventional approaches.
OBJECTIVES: We report the outcomes of robotic valve repair for degenerative mitral regurgitation (MR) in our Institution. METHODS: Between February 2012 and July 2016, 134 patients underwent robotic mitral valve (MV) repair with the da Vinci Si system. All the operations were performed through a mini-thoracotomy in the fourth right intercostal space, cardiopulmonary bypass and mild hypothermia. The clinical and echocardiographic follow-up was 100% complete. RESULTS: There was no hospital death. The mean cross-clamp and cardiopulmonary bypass time were 112±23 and 159±33 min, respectively. Pre-discharge echocardiograms showed none-to-mild residual MR in all patients. Median follow-up was 24.1 months. We observed 1 early and 4 late reoperations on the MV for an overall freedom from reoperation of 98.2% and 94.1% at 12 and 36 months, respectively. Furthermore, echocardiographic follow-up revealed freedom from recurrence of MR greater than Grade 1+ of 92.5% and 80.7% at 12 and 36 months, respectively. Nevertheless freedom from recurrence of MR greater than Grade 2+ was 97.2% at 12 and 36 months. CONCLUSIONS: Robotic MV repair is a feasible and safe option for the treatment of degenerative MR in selected patients with excellent perioperative outcomes. Early and midterm results are remarkable and are associated with low risk of late recurrence of MR and reoperation. Long-term follow-up is needed to confirm the durability of valve repair.
No takes yet. Share an insight, caveat, or question.
Navarra et al. (2017) conducted a cohort in Degenerative mitral regurgitation (n=134). Robotic mitral valve repair was evaluated on Hospital death. Robotic mitral valve repair for degenerative mitral regurgitation was safe, with 0% hospital mortality and 94.1% freedom from reoperation at 36 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: